ArticleJournal of cellular and molecular medicine2020
MicroRNA-612 inhibits cervical cancer progression by targeting NOB1.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Prognostic value of NOB1 expression levels in various cancers: a systematic review and meta-analysis.Biomarkers in medicine · 2024Pooled it
- To be or not to be: navigating the influence of MicroRNAs on cervical cancer cell death.Cancer cell international · 2025Review
- WTAP-Mediated mJournal of cellular and molecular medicine · 2024Article
- Polymorphisms in miRNA Genes Targeting the AMPK Signaling Pathway are Associated with Cervical Cancer Susceptibility in a Han Chinese Population.International journal of general medicine · 2024Article
- Relationship Between Expression of microRNA and Chemotherapy Resistance in Cervical Carcinoma.Applied biochemistry and biotechnology · 2023Article
- MicroRNAs, long non-coding RNAs, and circular RNAs and gynecological cancers: focus on metastasis.Frontiers in oncology · 2023Review
- NEAT1 can be a diagnostic biomarker in the breast cancer and gastric cancer patients by targeting XIST, hsa-miR-612, and MTRNR2L8: integrated RNA targetome interaction and experimental expression analysis.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2022Article
- Article
- Dietary stilbenes as modulators of specific miRNAs in prostate cancer.Frontiers in pharmacology · 2022Review
- Prognostic value ofFrontiers in genetics · 2022Article
- Abnormal Circulating Maternal miRNA Expression Is Associated with a Low (<4%) Cell-Free DNA Fetal Fraction.Diagnostics (Basel, Switzerland) · 2021Article
- The Hypoxia-Long Noncoding RNA Interaction in Solid Cancers.International journal of molecular sciences · 2021Review
- The role of HPV-induced epigenetic changes in cervical carcinogenesis (Review).Biomedical reports · 2021Review
- Small Non-Coding-RNA in Gynecological Malignancies.Cancers · 2021Review
- Simultaneous microRNA-612 restoration and 5-FU treatment inhibit the growth and migration of human PANC-1 pancreatic cancer cells.EXCLI journal · 2021Article
- MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy.Biomolecules · 2020Review
- MicroRNA-612 inhibits cervical cancer progression by targeting NOB1.Journal of cellular and molecular medicine · 2020Article
- Knockdown of MIR4435-2HG Suppresses the Proliferation, Migration and Invasion of Cervical Cancer Cells via Regulating the miR-128-3p/MSI2 Axis in vitro.Cancer management and research · 2020Article
- Long Noncoding RNA ST7-AS1 Upregulates TRPM7 Expression by Sponging microRNA-543 to Promote Cervical Cancer Progression.OncoTargets and therapy · 2020Article
- The Regulatory Role of circRNA_101308 in Cervical Cancer and the Prediction of Its Mechanism.Cancer management and research · 2020Article
Corrections and comments
- Retraction · 2024-06-19Error in Results and/or Conclusions · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, many studies have shown that microRNA (miR)-612 is involved in cancer progression. However, the role of miR-612 in cervical cancer remains unclear. The present study aims to investigate the biological effects of miR-612 on cervical cancer. The expression of miR-612 in cervical cancer tissues and cell lines was analysed by quantitative reverse transcription-polymerase chain reaction. The effect of miR-612 cell proliferation, migration, invasion and apoptosis was studied by appropriate methods. Protein expression was determined by Western blot analyses. Bioinformatics analysis and luciferase reporter assays were performed to clarify the relationship between miR-612 and nin one binding protein (NOB1). A xenograft model was established to examine the role of miR-612 in vivo tumorigenesis. Cervical cancer tissues and cell lines showed down-regulation of miR-612 expression, which was associated with the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage and lymph node metastasis. Functional assays revealed that miR-612 overexpression significantly suppressed cervical cancer cell proliferation, migration and invasion in vitro and delayed tumour growth in vivo. Mechanically, miR-612 targeted NOB1 in cervical cancer cells, revealing a negative correlation between miR-612 and NOB1in cervical cancer samples. NOB1 overexpression partially reversed the inhibitory effects of miR-612 overexpression in cervical cancer cells. Taken together, these findings indicate that miR-612 functions as a tumour suppressor in cervical cancer and suggest that miR-612 may be a potential target in the therapeutic intervention of this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.